回盛生物
(300871)
| 流通市值：35.19亿 | | | 总市值：35.19亿 |
| 流通股本：2.02亿 | | | 总股本：2.02亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,284,706,901.85 | 864,930,090.25 | 458,217,021.87 | 1,681,248,059.49 |
| 营业收入 | 1,284,706,901.85 | 864,930,090.25 | 458,217,021.87 | 1,681,248,059.49 |
| 二、营业总成本 | 1,070,679,426.96 | 702,717,089.76 | 363,647,395.52 | 1,414,179,951.34 |
| 营业成本 | 852,066,422.51 | 555,966,575.42 | 295,494,556.18 | 1,160,262,921.56 |
| 税金及附加 | 13,421,057.63 | 8,633,302.8 | 4,622,206.15 | 10,794,710.99 |
| 销售费用 | 69,164,462.58 | 46,853,229.47 | 22,433,637.16 | 83,921,698.46 |
| 管理费用 | 51,906,363.35 | 35,648,923.08 | 17,889,527.11 | 66,465,449.35 |
| 研发费用 | 79,453,532.3 | 53,775,263.96 | 24,402,366.07 | 79,818,086.34 |
| 财务费用 | 4,667,588.59 | 1,839,795.03 | -1,194,897.15 | 12,917,084.64 |
| 其中:利息费用 | 1,680,399.86 | 75,192 | -1,826,549.58 | 13,615,262.68 |
| 其中:利息收入 | 1,288,129.05 | 977,127.76 | 267,287.44 | 2,035,955.79 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 4,142,706.69 | 4,481,812.46 | -8,757,938.32 | 1,204,788.1 |
| 加:投资收益 | 1,151,152.85 | 605,161.33 | 1,284,599.53 | 8,886,087.59 |
| 资产处置收益 | 51,327,378.14 | 51,323,428.8 | - | - |
| 资产减值损失(新) | -2,036,438.47 | -2,490,683.09 | -1,598,388.78 | -2,227,243.12 |
| 信用减值损失(新) | -1,692,292.3 | -4,235,692.2 | -2,076,232.94 | -6,722,662.98 |
| 其他收益 | 25,479,830.38 | 21,678,911.26 | 3,910,833.21 | 22,265,481.51 |
| 四、营业利润 | 292,399,812.18 | 233,575,939.05 | 87,332,499.05 | 290,474,559.25 |
| 加:营业外收入 | 142,217.63 | 89,882.49 | 53,120.26 | 1,145,696.67 |
| 减:营业外支出 | 323,207.53 | 63,515.78 | 45,809.48 | 2,966,058.61 |
| 五、利润总额 | 292,218,822.28 | 233,602,305.76 | 87,339,809.83 | 288,654,197.31 |
| 减:所得税费用 | 32,128,839.6 | 27,160,234.97 | 9,095,307.5 | 35,165,546.6 |
| 六、净利润 | 260,089,982.68 | 206,442,070.79 | 78,244,502.33 | 253,488,650.71 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 260,089,982.68 | 206,442,070.79 | 78,244,502.33 | 253,488,650.71 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 258,839,386.25 | 205,760,223.49 | 77,674,741.18 | 253,155,975.55 |
| 少数股东损益 | 1,250,596.43 | 681,847.3 | 569,761.15 | 332,675.16 |
| 扣除非经常损益后的净利润 | 190,572,129.86 | 142,261,061.29 | 78,693,990.43 | 230,559,616.54 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.28 | 1.02 | 0.38 | 1.33 |
| (二)稀释每股收益 | 1.28 | 1.02 | 0.38 | 1.29 |
| 九、综合收益总额 | 260,089,982.68 | 206,442,070.79 | 78,244,502.33 | 253,488,650.71 |
| 归属于母公司股东的综合收益总额 | 258,839,386.25 | 205,760,223.49 | 77,674,741.18 | 253,155,975.55 |
| 归属于少数股东的综合收益总额 | 1,250,596.43 | 681,847.3 | 569,761.15 | 332,675.16 |
| 公告日期 | 2026-10-23 | 2026-08-15 | 2026-04-28 | 2026-04-17 |
| 审计意见(境内) | | | | 标准无保留意见 |